DDInter1397 DDInter1477
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is proposed to primarily regulate tumor necrosis factor (TNF) pathways and modulate cellular oxidation. The FDA first approved pirfenidone alongside [nintedanib] as one of the first drugs to treat IPF.
Paroxetine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pirfenidone
Paroxetine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Rifampicin
Rifampicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pirfenidone
Paroxetine {u} (Compound) downregulates {v} (Gene) HSPA8
HSPA8 {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pirfenidone
Paroxetine {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pirfenidone
Paroxetine {u} (Compound) downregulates {v} (Gene) HSPA8
HSPA8 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Vemurafenib {u} may lead to a major life threatening interaction when taken with {v} Pirfenidone
Paroxetine {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Duloxetine
Duloxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pirfenidone
Paroxetine {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Amiodarone
Amiodarone {u} may lead to a major life threatening interaction when taken with {v} Pirfenidone
Paroxetine {u} (Compound) upregulates {v} (Gene) HERPUD1
HERPUD1 {u} (Gene) is downregulated by {v} (Compound) Fluvoxamine
Fluvoxamine {u} may lead to a major life threatening interaction when taken with {v} Pirfenidone
Paroxetine {u} (Compound) downregulates {v} (Gene) EZH2
EZH2 {u} (Gene) is upregulated by {v} (Compound) Gemfibrozil
Gemfibrozil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pirfenidone
Paroxetine {u} (Compound) upregulates {v} (Gene) HERPUD1
HERPUD1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Vemurafenib {u} may lead to a major life threatening interaction when taken with {v} Pirfenidone
Paroxetine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Pirfenidone
Paroxetine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Rifampicin (Compound) and Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone
Paroxetine (Compound) downregulates HSPA8 (Gene) and HSPA8 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Pirfenidone
Paroxetine (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Pirfenidone
Paroxetine (Compound) downregulates HSPA8 (Gene) and HSPA8 (Gene) is downregulated by Vemurafenib (Compound) and Vemurafenib may lead to a major life threatening interaction when taken with Pirfenidone
Paroxetine (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Duloxetine (Compound) and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone
Paroxetine (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Amiodarone (Compound) and Amiodarone may lead to a major life threatening interaction when taken with Pirfenidone
Paroxetine (Compound) upregulates HERPUD1 (Gene) and HERPUD1 (Gene) is downregulated by Fluvoxamine (Compound) and Fluvoxamine may lead to a major life threatening interaction when taken with Pirfenidone
Paroxetine (Compound) downregulates EZH2 (Gene) and EZH2 (Gene) is upregulated by Gemfibrozil (Compound) and Gemfibrozil may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone
Paroxetine (Compound) upregulates HERPUD1 (Gene) and HERPUD1 (Gene) is upregulated by Vemurafenib (Compound) and Vemurafenib may lead to a major life threatening interaction when taken with Pirfenidone